Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 1/20 | 0.66 |
| ▸ | CA1 | P00915 | 1/20 | 0.66 |
| ▸ | CA2 | P00918 | 1/20 | 0.66 |
| ▸ | CA9 | Q16790 | 1/20 | 0.66 |
| ▸ | MAPT | P10636 | 1/20 | 0.62 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.60 |
| ▸ | MEN1 | O00255 | 2/20 | 0.59 |
| ▸ | GAA | P10253 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21579855 | 0.92 | POLB (0.65) | CA12CA1CA2CA9MAPT | |
| SCHEMBL5073509 | 0.92 | MTNR1A (0.56) | CA12CA1CA2CA9SMN1; SMN2 | |
| SCHEMBL6987265 | 0.91 | KMT2A (0.57) | CA12CA1CA2CA9MAPT | |
| SCHEMBL16416372 | 0.88 | CA12 (0.51) | CA12CA1CA2CA9SMN1; SMN2 | |
| SCHEMBL9689182 | 0.88 | CA12 (0.51) | CA12CA1CA2CA9SMN1; SMN2 | |
| SCHEMBL5913864 | 0.88 | CA12 (0.51) | CA12CA1CA2CA9MAPT | |
| SCHEMBL10223234 | 0.87 | CA12 (0.68) | CA12CA1CA2CA9MAPT | |
| SCHEMBL9786087 | 0.87 | CA12 (0.50) | CA12CA1CA2CA9ALDH1A1 | |
| SCHEMBL7271744 | 0.87 | CA12 (0.50) | CA12CA1CA2CA9MAPT | |
| SCHEMBL10558894 | 0.85 | SMN1; SMN2 (0.49) | CA12CA1CA2CA9MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2010044054-A1 | PHENETHYLAMIDE DERIVATIVES AND THEIR HETEROCYCLIC ANALOGUES | ACTELION PHARMACEUTICALS LTD (CH) | 2010-04-22 | — | — | WO | claimed |
| EP-2644597-B1 | Novel method for synthesising ivabradine and its pharmaceutically acceptable acid addition salts | SERVIER LAB (FR) | 2016-01-13 | — | — | EP | disclosed |
| CN-103450082-B | The novel method of the additive salt of synthesis of ivabradine and itself and pharmaceutically acceptable acid | LABORATOIRES THERWILL (FR) | 2015-11-18 | — | — | CN | disclosed |
| US-8835627-B2 | Process for the synthesis of ivabradine and addition salts thereof with a pharmaceutically acceptable acid | LES LABORATOIRES SERVIER (FR) | 2014-09-16 | — | — | US | disclosed |
| US-20130261298-A1 | PROCESS FOR THE SYNTHESIS OF IVABRADINE AND ADDITION SALTS THEREOF WITH A PHARMACEUTICALLY ACCEPTABLE ACID | LES LABORATOIRES SERVIER (FR) | 2013-10-03 | — | — | US | disclosed |
| WO-2013144500-A1 | NOVEL METHOD FOR SYNTHESIZING IVABRADINE AND ITS ADDITION SALTS WITH A PHARMACEUTICALLY ACCEPTABLE ACID | LES LABORATOIRES SERVIER (FR) | 2013-10-03 | — | — | WO | disclosed |
| EP-2644597-A1 | Novel method for synthesising ivabradine and its pharmaceutically acceptable acid addition salts | Les Laboratoires Servier (FR) | 2013-10-02 | — | — | EP | disclosed |
| US-20110212968-A1 | PHENETHYLAMIDE DERIVATIVES AND THEIR HETEROCYCLIC ANALOGUES | ACTELION PHARMACEUTICALS LTD. (CH) | 2011-09-01 | — | — | US | disclosed |
| EP-2334643-A1 | PHENETHYLAMIDE DERIVATIVES AND THEIR HETEROCYCLIC ANALOGUES | Actelion Pharmaceuticals Ltd. (CH) | 2011-06-22 | — | — | EP | disclosed |
| WO-2010044054-A1 | PHENETHYLAMIDE DERIVATIVES AND THEIR HETEROCYCLIC ANALOGUES | ACTELION PHARMACEUTICALS LTD (CH) | 2010-04-22 | — | — | WO | disclosed |
| EP-1150946-B1 | ARYLALKANOYL DERIVATIVES, PROCESSES FOR THEIR PREPARATION, THEIR USE AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | AVENTIS PHARMA GMBH (DE) | 2005-03-30 | — | — | EP | disclosed |
| US-4906634-A | Novel N-[4-(aminosubstituted)phenyl]methanesulfonamides and their use as cardiovascular agents | SCHERING A.G. (DE) | 1990-03-06 | — | — | US | disclosed |
| EP-0332570-A2 | Novel-N-(4-(Aminosubstituted)phenyl) methanesulfonamides and their use as cardiovascular agents | SCHERING AKTIENGESELLSCHAFT (DE) | 1989-09-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130261298-A1 | PROCESS FOR THE SYNTHESIS OF IVABRADINE AND ADDITION SALTS THEREOF WITH A PHARMACEUTICALLY ACCEPTABLE ACID | CYP4F2, CYP2F1, CYP2D6 | CA12 3419/4885CA1 3006/4885CA2 586/4885 |
| US-20110212968-A1 | PHENETHYLAMIDE DERIVATIVES AND THEIR HETEROCYCLIC ANALOGUES | HCRTR2, HCRTR1, HRH3 | CA12 3489/4885CA1 2155/4885CA2 985/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.